Researchers report that GLP-1 medications used for type 2 diabetes and weight loss, including Ozempic, Mounjaro, and Wegovy, are associated with a higher risk of hair loss. Multiple outlets describe a large study involving about 50,000 people. The study compares GLP-1 agonist users with users of two other common classes of diabetes medications and finds that hair loss, or alopecia, occurs more often in the GLP-1 group. Reported cases are described as mainly non-scarring, meaning the hair loss may be reversible. Several sources also note that complaints of hair loss have been raised with regulators previously, and the new research adds to that discussion by quantifying the association. While the overall increase is described as relatively small in absolute terms, the findings suggest a potential side effect that patients and clinicians may want to consider. Coverage also highlights that GLP-1 side effects have been widely discussed in public and that evidence quality can vary across different reported effects; in this case, the outlets focus on the new study’s results in a diabetes and weight loss population.